Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy.

摘要: Purpose of review Interventional oncology (IO) loco-regional treatments are widely utilized in clinical practice. However, local tumor control rates still variable. There is a need to identify and develop novel biomarkers prognosticators following IO therapies. Here, we the current literature on molecular IO, mainly focusing patients with liver lung cancers. Recent findings RAS mutation prognosticator for colorectal metastases. Several promising serum metabolites, gene signatures, circulating nucleotides, peptides being evaluated hepatocellular carcinoma. Ki-67 independent risk factors progression ablation cancer. The relevant interplay between specific therapies outcomes has brought new vision management Further evolution personalized interventional accordingly should improve oncologic receiving